mk-0646 Pages on BioPortfolio:

BioPortfolio - mk-0646
mk-0646 - BioPortfolio. ... A Phase II Clinical and Translational Study of MK- 0646 in Patients with Metastatic Neuroendocrine Tumors - Saltz, Leonard, . ...
http://www.bioportfolio.com/search/mk-0646.html...

BioPortfolio - 2008 carcinoid tumors conference
Commercial Appeal: Oct 25 2008 5:44AM Matching: carcinoid tumor ... to find this page: dupont carcinoid | 2008 carcinoid tumors conference | mk-0646 | . ...
http://www.bioportfolio.com/search/2008_carcinoid_tumors_con...

BioPortfolio - IGF2R - insulin-like growth factor 2 receptor
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer, Pancreatic Cancer; Pancreatic Adenocarcinoma ...
http://www.bioportfolio.com/gene/3482-IGF2R.html...

BioPortfolio - Carcinoid Tumor
Recent Search Terms used to find this page: dupont carcinoid | 2008 carcinoid tumors conference | mk-0646 | . Browse BioPortfolio's InDepth service ...
http://www.bioportfolio.com/indepth/Carcinoid_Tumor.html...

Results from other life science and pharmaceutical sites:

Sloan-Kettering - A Phase II Clinical and Translational Study of ...
A Phase II Clinical and Translational Study of MK-0646 in Patients with Metastatic Neuroendocrine Tumors - Saltz, Leonard, MD [Protocol 07-162]
http://www.mskcc.org/mskcc/html/2270.cfm?IRBNO=07-162...

Merck News Item
27 May 2008 ... Results from Studies of Other Investigational Merck Cancer Medicines, Including the IGF-1R inhibitor (MK-0646), also Presented at ASCO ...
http://www.merck.com/newsroom/press_releases/research_and_de...

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer ...
Treatment of A431 GR cells with the IGFIR antibody (Mk-0646) or AEW541 resulted in loss of PI3K binding to IRS-1 (Figure 3B) but did not affect binding to ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24...

Achieving Results. Regaining Leadership. Accelerating Discovery.
Neurologic, MK-4305. Neurologic, MK-8998. Ophthalmic, MK-0140. Parkinson’s Disease, MK-0657. Psychiatric Disease, MK-5757. Cancer, MK-0646. phase 11 ...
http://www.merck.com/finance/annualreport/ar2007/pdf/merck-a...

Partnership between small biotech and big pharma Gregory J ...
a therapeutic monoclonal antibody (mAb) (MK-0646; Pierre ... Cancer, MK-0646. Endocrine, MK-0974. Flu vaccine. Glaucoma, MK-0994. Obesity, Nastech PYY3-36**
...
http://www.biomedcentral.com/content/pdf/cd-680042.pdf...

Merck’s research pipeline
Cancer, MK-0646. Cancer vaccine. Cardiovascular, MK-0448. Diabetes, MK-0941. Diabetes, MK-0893. Diabetes, MK-0533. Flu vaccine. Insomnia, MK-0454 ...
http://www.merck.com/finance/annualreport/ar2005/pdf/pipelin...

Commercial interest waxes for IGF-1 blockers : Article : Nature ...
... New Jersey–based Merck's MK-0646—all in phase 2 trials for head-and-neck cancer, advanced solid tumors and metastatic colon cancer, respectively. ...
http://www.nature.com/nbt/journal/v26/n7/full/nbt0708-719.ht...

Financial Section
VX-680*, MK-0646*. Cancer Vaccine. Cardiovascular Disease. MK-0448. Diabetes. MK -0941, MK-0893, MK-0533. Endocrine. MK-0974. Flu Vaccine. Glaucoma. MK-0994 ...
http://www.merck.com/finance/annualreport/ar2005/pdf/Merck_2...

Table 1 : Commercial interest waxes for IGF-1 blockers : Nature ...
Merck (Whitehouse Station, New Jersey)/Pierre Fabre (Paris), MK-0646 (humanized IgG1 antibody targeting IGF-1R extracellular domain), Phase 2 ...
http://www.nature.com/nbt/journal/v26/n7/fig_tab/nbt0708-719...

2 Forward-Looking Statement This presentation contains "forward ...
Cancer, MK-0646. Cancer, MK-0457. Overactive Bladder MK-0634 ... Cancer,MK-0646. Licensed, alliance, or acquisition *Antigen licensed from Intercell AG ...
http://www.merck.com/finance/pipeline.swf...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.